Centene price target lowered to $80 from $92 at Mizuho

Mizuho lowered the firm’s price target on Centene to $80 from $92 and keeps a Neutral rating on the shares post the Q4 results. Given the "unprecedented growth" in the health exchanges, Medicaid redetermination headwinds, and potential reimbursement changes for Medicare Advantage plans, the analyst no longer believes Centene can trade at previous multiples.